Diabetic retinopathy affects approximately 26% of U.S. adults with diabetes, including about 1.84 million people with vision-threatening disease. Severe non-proliferative retinopathy, proliferative retinopathy, and diabetic macular edema can progress silently before vision loss becomes apparent. AAVBC’s position is that waiting for visual symptoms is a preventable failure point. Primary care teams should confirm that retinal screening is current, close referral loops, and document diabetes type, retinopathy stage, macular-edema status, laterality, and treatment status with the specificity the condition requires.
AAVBC's Diabetic Eye Disease Quick Reference Guide brings together AAO, ADA, and Endocrine Society guidance on type 1 and type 2 screening intervals, severity staging, ICD-10 and HCC/RAF V28 coding, MEAT documentation, treatment escalation, comorbidity screening, and case-based coding reminders. This guide supports consistent, individualized clinical decision-making, helping care teams recognize and stage diabetic eye disease accurately, document clinical complexity completely, and coordinate care with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of diabetic eye disease — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Diabetic retinopathy affects approximately 26% of U.S. adults with diabetes, including about 1.84 million people with vision-threatening disease. Severe non-proliferative retinopathy, proliferative retinopathy, and diabetic macular edema can progress silently before vision loss becomes apparent. AAVBC’s position is that waiting for visual symptoms is a preventable failure point. Primary care teams should confirm that retinal screening is current, close referral loops, and document diabetes type, retinopathy stage, macular-edema status, laterality, and treatment status with the specificity the condition requires.
AAVBC's Diabetic Eye Disease Quick Reference Guide brings together AAO, ADA, and Endocrine Society guidance on type 1 and type 2 screening intervals, severity staging, ICD-10 and HCC/RAF V28 coding, MEAT documentation, treatment escalation, comorbidity screening, and case-based coding reminders. This guide supports consistent, individualized clinical decision-making, helping care teams recognize and stage diabetic eye disease accurately, document clinical complexity completely, and coordinate care with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of diabetic eye disease — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
